1-(Benzyloxycarbonyl)-4-(1-ethyl-1-hydroxypropyl)piperidine | 173457-46-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(Benzyloxycarbonyl)-4-(1-ethyl-1-hydroxypropyl)piperidine
• 英文别名: 1-(Benzyloxycarbonyl)-4-(1-ethyl-1-hydroxypropyl)piperdine；Benzyl 4-(3-hydroxypentan-3-yl)piperidine-1-carboxylate
• CAS: 173457-46-0
• 化学式: C₁₈H₂₇NO₃
• 分子量: 305.417
• InChiKey: YZMODTZLGAKDQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(Benzyloxycarbonyl)-4-(1-ethyl-1-hydroxypropyl)piperidine 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 为溶剂， 生成 4-(1-ethyl-1-hydroxypropyl)piperidine
  参考文献：
  名称：

  4-Alkylpiperidines related to SR-48968: Potent antagonists of the neurokinin-2 (NK2) receptor

  摘要：

  A series of 4-alkylpiperidine derivatives related to the potent neurokinin-2 (NK2) receptor antagonist SR-48968 (1) is described. Simple aliphatic derivatives were found to be poorly active, but appropriate placement of an alcohol functional group afforded compounds that were of similar activity to 1. Several representatives in this series, such as the 4-(1-hydroxy-1-ethylpropyl)piperidine (14), were found to exhibit oral activity in a model of labored abdominal breathing in guinea pigs. These results expand the latitude of substituents available in this region of this series of NK2 receptor antagonists. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00037-7
• 作为产物：
  描述：

  哌啶-4-甲酸乙酯 在 三乙胺 作用下， 以 四氢呋喃 、 氯仿 为溶剂， 生成 1-(Benzyloxycarbonyl)-4-(1-ethyl-1-hydroxypropyl)piperidine
  参考文献：
  名称：

  4-Alkylpiperidines related to SR-48968: Potent antagonists of the neurokinin-2 (NK2) receptor

  摘要：

  A series of 4-alkylpiperidine derivatives related to the potent neurokinin-2 (NK2) receptor antagonist SR-48968 (1) is described. Simple aliphatic derivatives were found to be poorly active, but appropriate placement of an alcohol functional group afforded compounds that were of similar activity to 1. Several representatives in this series, such as the 4-(1-hydroxy-1-ethylpropyl)piperidine (14), were found to exhibit oral activity in a model of labored abdominal breathing in guinea pigs. These results expand the latitude of substituents available in this region of this series of NK2 receptor antagonists. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00037-7

文献信息

• Piperidine derivatives useful as neurokinin antagonists
  申请人：Zeneca Limited

  公开号：US05635509A1

  公开（公告）日：1997-06-03

  Compounds of formula I ##STR1## wherein Q.sup.1, Q.sup.2, Q.sup.3, and Q.sup.4 have any of the meanings given in the specification, their N-oxides, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  式I的化合物##STR1##其中Q.sup.1、Q.sup.2、Q.sup.3和Q.sup.4具有规范中给定的任何含义，它们的N-氧化物以及它们的药用盐是神经激肽A的非肽类拮抗剂，用于治疗哮喘等。还公开了制药组合物、制备式I化合物和中间体的方法。
• [EN] PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTEINE KINASE 2-INDOLINONE A SUBSTITUTION PYRROLE
  申请人：SUGEN INC

  公开号：WO2001060814A2

  公开（公告）日：2001-08-23

  The present invention relates to pyrrole substituted 2-indolinone compounds of formula (I): and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefor are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.

  本发明涉及式(I)的吡咯取代的2-吲哚酮化合物及其药学上可接受的盐，该化合物可以调节蛋白激酶的活性，因此预计在预防和治疗蛋白激酶相关的细胞疾病，如癌症方面有用。
• Heterocyclic compounds
  申请人：ZENECA LIMITED

  公开号：EP0680962A2

  公开（公告）日：1995-11-08

  Compounds of formula I wherein Q1, Q2, Q3, Q4, Q5 and T have any of the meanings given in the specification, their N-oxides, their quaternary ammonium salts, and their pharmaceutically acceptable salts are nonpeptide antagonists of neurokinin A and useful for the treatment of asthma, etc. Also disclosed are pharmaceutical compositions, processes for preparing the compounds of formula I and intermediates.

  式 I 的化合物 其中 Q1、Q2、Q3、Q4、Q5 和 T 具有说明书中给出的任何含义，它们的 N-氧化物、季铵盐和它们的药学上可接受的盐是神经激肽 A 的非肽拮抗剂，可用于治疗哮喘等。还公开了药物组合物、制备式 I 化合物的工艺和中间体。
• IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS
  申请人：Sugen, Inc.

  公开号：EP1233943A2

  公开（公告）日：2002-08-28
• PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS
  申请人：Sugen, Inc.

  公开号：EP1255752A2

  公开（公告）日：2002-11-13